《大行報告》高盛:保誠(02378.HK)去年下半年新業務利潤增長優預期
高盛發表報告指,保誠(02378.HK)去年下半年新業務利潤增長好過預期,尤其在香港及東盟市場,優於預期的表現主要由利潤率提升所推動,由去年上半年的49%增至去年下半年的57%,各大主要市場均有改善。今年首兩個月銷售持續增長,若果利潤率維持擴張,將會推動今年新業務利潤再有強勁增長。
報告指,去年保誠本港新業務利潤14.11億美元,按年升267%,年度保費等值銷售額(APE)增長276%,利潤率穩定,下半年產品組合漸改善,儲蓄產品規模復常,健康及保障型產品銷售改善。
該行對保誠H股維持「買入」評級,目標價186元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.